ArticleFrontiers in endocrinology2026
Opportunistic osteoporosis screening in primary hyperparathyroidism using routine CT: validation of a standardized vertebral cBMD index.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the diagnostic performance of a routine CT-derived vertebral bone density index, the standardized percentage change in bone mineral density (cBMD), for detecting osteoporosis in patients with primary hyperparathyroidism (PHPT), and to explore its association with parathyroid hormone (PTH) compared to Quantitative CT (QCT). Materials and methods: This retrospective study included 175 consecutive patients with biochemically confirmed PHPT. QCT-derived volumetric bone mineral density (vBMD), obtained using asynchronous calibration, served as the reference standard. cBMD was calculated from routine non-contrast CT images using a phantom-less normalization method. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Multivariable logistic regression was used to assess the incremental diagnostic value of cBMD beyond demographic and biochemical variables, and multivariable linear regression was performed to compare independent determinants of cBMD and QCT-vBMD. Results: Vertebral cBMD showed a strong linear correlation with QCT-vBMD across T12-L3 (r > 0.95, P< 0.001). For osteoporosis detection, L2-cBMD achieved an area under the ROC curve (AUC) of 0.992, with 100.0% sensitivity and 92.5% specificity. Incorporation of L2-cBMD into multivariable models significantly improved diagnostic performance compared with models including demographic and biochemical variables alone (AUC increase from 0.937 to 0.996, P< 0.001). In linear regression analyses adjusted for age and body mass index, cBMD showed an independent association with serum PTH levels (P = 0.010), whereas QCT-vBMD did not (P = 0.398). Conclusion: cBMD is a robust, phantom-less tool derived from routine CT images that demonstrates high diagnostic accuracy for osteoporosis in PHPT. Its association with serum PTH highlights its potential utility as a complementary imaging biomarker for opportunistic bone health screening in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.